Company Overview
Company Type: Private Company
Website: www.adarepharmasolutions.com
Global Number of Employees (Latest): -
Year Founded: 2015
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Adare Pharmaceuticals, Inc., a contract development, and manufacturing organization, develops, manufactures, and markets pharmaceutical technologies for customers worldwide. The company offers patient-centric solutions, such as taste-masked products and alternative dosage forms; a customized drug release platform, which releases drug profiles tailored to therapeutic performance; and a bioavailability enhancement platform that improves solubility within the gastrointestinal tract. In addition, it also develops and provides Stratµm, a microencapsulation technology; Optimμm, an oral dose microcapsules; Unisun, for intratympanic delivery; and Advatab for oral disintegration. Adare Pharmaceuticals, Inc. was formerly known as Aptalis Pharmatech, Inc. The company was incorporated in 2015 and is based in Lawrenceville, New Jersey. It has a manufacturing and formulation, and research and development facility in Vandalia, Ohio. It has manufacturing facilities in Canada, Italy, and France. Adare Pharmaceuticals, Inc. is a former subsidiary of Allergan plc.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Global Number of Employees (Latest)
-
Net Debt
-
U.S. Number of Employees 2022
 417
U.S. Number of Employees 2021
 244
U.S. Last Year Employee Growth %
 70.9
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Sellig, Thomas 
Chief Executive Officer
Perry, Matt 
VP of Operations & Chief Supply Chain Officer
Ortenzi, Giovanni 
VP of Pharmaceutical Development & CTO
Bélanger, Daniel
Vice President of Human Resources
Dhall, Vipan 
Chief Scientific Officer
Hamilton, Troy 
VP & Global Head of Specialty Pharmaceuticals
Muschert, Robert 
Chief Commercial Officer
Richardson, Peter C.
Chief Medical Officer and VP of Research & Development
Roedder, Ludger 
President of Biome

Key Board Members
Name
Title
Sharma, Vivek 
Chairman
Schilling, John R.
Director
Sisitsky, Todd B.
Director


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
Princeton Pike Corporate Center 1200 Lenox Drive Suite 100 | Lawrenceville, NJ | 08648 | United States
Phone: 609 450 1312   Fax: 908 927 9648

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Investment Coverage
Frazier Management, L.L.C.
Sep-22-2020
Majority
-
-
Clarissa Berman, Jack Trunzo, Jeremy Janson, Nathan Every, William Mitchell
Thomas H. Lee Partners, L.P.
Sep-22-2020
Unknown
-
-
Aashish Goswami, Joshua Nelson, Megan Preiner

Prior Investors
TPG Capital, L.P. (Katherine Wood, Paul Hackwell, Stephen O’Keefe)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Frontida Biopharm, Inc.
Frontida Biopharm, Inc. is a contract development and manufacturing organization that supports biopharmaceutical companies in the scale-up and commercial manufacture of immediate and controlled release oral solid dose products. The company provides highly potent active ingredient (HPAI) products and combination products, as well as DEA schedules II – V products. The company also provides clinical trial materials manufacturing, serialized packaging, warehousing, and stability services. Frontida Biopharm, Inc. was incorporated in 2015 and is headquartered in Exton, Pennsylvania. As of December 1, 2021, Frontida Biopharm, Inc. operates as a subsidiary of Adare Pharmaceuticals, Inc.

United States and Canada
Life Sciences Tools and Services
31.00
-
-
Orbis Biosciences, Inc.
Orbis Biosciences, Inc. develops controlled-release delivery systems for pharmaceutical, consumer product, chemical, and food and beverage industries. Its precision particle fabrication technology enables companies to develop new product lines and reinvent their current portfolios through control of particle parameters. The company was incorporated in 2007 and is based in Lenexa, Kansas. As of April 30, 2020, Orbis Biosciences, Inc. operates as a subsidiary of Adare Pharmaceuticals, Inc.

United States and Canada
Biotechnology
-
-
-
ParvuletTM Technology Platform of Egalet Corporation
As per the transaction announced on April 15, 2019, ParvuletTM Technology Platform of Egalet Corporation was acquired by Adare Pharmaceuticals, Inc. ParvuletTM Technology Platform of Egalet Corporation develops a technology to enable single-dose formulation of taste-maske oral medications. The asset is located in the United States.

United States and Canada
Pharmaceuticals
-
-
-
Viactiv Holdings, LLC
Viactiv Holdings, LLC develops and offers a calcium supplement chew. The company was incorporated in 2012 and is based in Greenwich, Connecticut. As of January 4, 2017, Viactiv Holdings, LLC operates as a subsidiary of Adare Pharmaceuticals, Inc.

United States and Canada
Personal Care Products
-
-
-
Adare Pharmaceuticals Srl
Mfg Pharmaceutical Preparations

Europe
Pharmaceuticals
63.00
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jul-03-2023
Jul-03-2023
Merger/Acquisition
Seller
Adare Pharmaceuticals SAS
DSM-Firmenich AG (ENXTAM:DSFIR)
Adare Pharmaceuticals, Inc.
300.09
Dec-01-2021
Dec-01-2021
Merger/Acquisition
Buyer
Frontida Biopharm, Inc.
Adare Pharmaceuticals, Inc.

-
May-18-2021
Jun-01-2021
Merger/Acquisition
Seller
Activ Nutritional, LLC.
Guardion Health Sciences, Inc. (NasdaqCM:GHSI)
Adare Pharmaceuticals, Inc.
25.95
Sep-22-2020
Sep-22-2020
Merger/Acquisition
Target
Adare Pharmaceuticals, Inc.
Thomas H. Lee Partners, L.P.,Frazier Management, L.L.C.
TPG Capital, L.P.
-
May-04-2020
Apr-30-2020
Merger/Acquisition
Buyer
Orbis Biosciences, Inc.
Adare Pharmaceuticals, Inc.

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jul-03-2023
M&A Transaction Closings
DSM-Firmenich AG (ENXTAM:DSFIR) acquired Adare BIOME from Adare Pharmaceuticals, Inc. for enterprise value of €280 million.
May-16-2023
Company Conference Presentations
Adare Pharmaceuticals, Inc. Presents at BIONNALE 2023, May-16-2023
Nov-01-2022
Company Conference Presentations
Adare Pharmaceuticals, Inc. Presents at CPhI Worldwide, Nov-01-2022
Jul-26-2022
Company Conference Presentations
Adare Pharmaceuticals, Inc. Presents at Webinar 3: Oral & Other Non-Injectable Technologies, Jul-26-2022
Jan-06-2022
Executive Changes - CEO
Adare Pharma Solutions Announces Appointment of Tom Sellig as Chief Executive Officer

Competitors
Avara Pharmaceutical Services, Inc., BioDuro-Sundia, Bioserv Corporation, Catalent, Inc. (NYSE:CTLT), Corden Pharma GmbH, CoreRx, Inc., Frontage Laboratories, Inc., Metrics, Inc., Patheon N.V., Pharmaceutics International, Inc., Quotient Sciences Limited, Recipharm AB (publ), Societal CDMO, Inc. (NasdaqCM:SCTL)

M&A Advisors
Debevoise & Plimpton LLP, Duane Morris LLP, Kirkland & Ellis LLP, Kirkland & Ellis LLP, RBC Capital Markets, LLC


Advisors
M&A Advisors
Debevoise & Plimpton LLP, Duane Morris LLP, Kirkland & Ellis LLP, Kirkland & Ellis LLP, RBC Capital Markets, LLC


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 15, 2023 07:41 AM
Adare Pharmaceuticals, Inc.
Adare Pharma Solutions - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
27
GlobalData

Sep 14, 2023 08:30 AM
Adare Pharmaceuticals, Inc.
Adare Pharma Solutions
Reports
83
GlobalData

Aug 29, 2023 01:52 AM
Adare Pharmaceuticals, Inc.
Adare Pharma Solutions - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
37
GlobalData

Jun 19, 2023 05:39 AM
Adare Pharmaceuticals, Inc.
Adare Pharma Solutions
Reports
82
GlobalData

Jun 09, 2023 07:29 AM
Adare Pharmaceuticals, Inc.
Adare Pharma Solutions - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
27
GlobalData

May 17, 2023 05:38 AM
Adare Pharmaceuticals, Inc.
Adare Pharma Solutions - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
37
GlobalData

Mar 17, 2023 04:13 AM
Adare Pharmaceuticals, Inc.
Adare Pharma Solutions
Reports
78
GlobalData

Mar 11, 2023 07:28 AM
Adare Pharmaceuticals, Inc.
Adare Pharma Solutions - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
27
GlobalData

Feb 10, 2023 04:21 AM
Adare Pharmaceuticals, Inc.
Adare Pharma Solutions - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
37
GlobalData

Dec 27, 2022 03:05 AM
Adare Pharmaceuticals, Inc.
Adare Pharma Solutions - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
39


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.


Upcoming Events
Date/Time
Type
Oct-16-2023
Conferences
Oct-16-2023 2:25 PM (EDT)
Company Conference Presentations
* Future Events are subject to change.

Key Board Members Details
Name
Title
Phone
Fax
Email
Sharma, Vivek 
Chairman
609 450 1312
908 927 9648

Schilling, John R.
Director
609 450 1312
908 927 9648

Sisitsky, Todd B.
Director
609 450 1312
908 927 9648

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Sellig, Thomas 
Chief Executive Officer
609 450 1312
908 927 9648

Perry, Matt 
VP of Operations & Chief Supply Chain Officer
609 450 1312
908 927 9648
-
Ortenzi, Giovanni 
VP of Pharmaceutical Development & CTO
609 450 1312
908 927 9648
-
Bélanger, Daniel
Vice President of Human Resources
609 450 1312
908 927 9648
-
Dhall, Vipan 
Chief Scientific Officer
609 450 1312
908 927 9648

Hamilton, Troy 
VP & Global Head of Specialty Pharmaceuticals
609 450 1312
908 927 9648

Muschert, Robert 
Chief Commercial Officer
609 450 1312
908 927 9648

Richardson, Peter C.
Chief Medical Officer and VP of Research & Development
609 450 1312
908 927 9648

Roedder, Ludger 
President of Biome
609 450 1312
908 927 9648

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
